SHAREHOLDER ALERT: WeissLaw LLP Reminds XLRN, JMP, ECHO, and KDMN Shareholders About Its Ongoing Investigations

-

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
WeissLaw LLP
305 Broadway, 7 th Floor
New York , NY  10007
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

Acceleron Pharma Inc. (NASDAQ: XLRN)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Acceleron Pharma Inc. (NASDAQ: XLRN) in connection with the proposed acquisition of the Company by Merck & Co., Inc. ("Merck") (NYSE: MRK), via a tender offer.  Under the terms of the merger agreement, XLRN shareholders will receive $180.00 per share in cash for each share of XLRN common stock that they hold.  If you own XLRN shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/xlrn

JMP Group LLC (NYSE: JMP)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of JMP Group LLC (NYSE: JMP) in connection with the proposed acquisition of the company by Citizens Financial Group Inc.  Under the terms of the merger agreement, JMP shareholders will receive $7.50 per share in cash for each share of JMP common stock that they hold.  If you own JMP shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/jmp

Echo Global Logistics, Inc. (NASDAQ: ECHO)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Echo Global Logistics, Inc. (NASDAQ: ECHO) in connection with the proposed acquisition of the company by funds managed by The Jordan Company, L.P.  Under the terms of the merger agreement, ECHO shareholders will receive $48.25 per share in cash for each share of ECHO stock that they hold.  If you own ECHO shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/echo

Kadmon Holdings, Inc. (NASDAQ: KDMN)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Kadmon Holdings, Inc. (NASDAQ: KDMN) in connection with the proposed acquisition of the company by Sanofi ("Sanofi").  Under the terms of the merger agreement, the company's shareholders will receive $9.50 per share in cash for each share of KDMN stock that they hold.  If you own KDMN shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/kadmon-holdings-inc

View original content to download multimedia: https://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-reminds-xlrn-jmp-echo-and-kdmn-shareholders-about-its-ongoing-investigations-301395829.html

SOURCE WeissLaw LLP

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)
 Thian Chew, CEO of Invion

New Deal Could Spark Invion’s Entry into Pet Cancer Market, CEO Says

Invion’s (ASX:IVX,OTC Pink:IVIXF) Photosoft cancer treatment technology has entered an important milestone, thanks to a new collaboration deal with Taiwanese firm Protect Animal Health, to undertake studies to treat cancer in pets.“The significance of this recent collaboration is (that) now... Keep Reading...
Appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth

Appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system ("CNS") disorders, is delighted to announce the appointment of Paul Carter as Non-Executive Director, effective 27 October 2025.Paul Carter is a highly... Keep Reading...
Medicine capsule showing active ingredients.

5 Biggest Pharma Stocks in 2025

The pharmaceutical industry is a major player in the overall life science sector, responsible for developing and manufacturing the majority of prescription drugs. Companies in this space are constantly researching and creating innovative treatments for various medical conditions. In recent... Keep Reading...
Seegnal Inc. (TSXV:SEGN)

Seegnal Inc. Announces Extension of Maccabi Health Services Contract

Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Corporation"), a global leader in SaaS clinical division support solutions, is pleased to announce that effective September 8, 2025, it has amended its contract with Maccabi Health Services ("Maccabi") for an additional six years and has also expanded... Keep Reading...
Numinus Wellness Inc. Announces Third Quarter Fiscal 2025 Results

Numinus Wellness Inc. Announces Third Quarter Fiscal 2025 Results

All financial results are reported in Canadian dollars unless otherwise stated. Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) (FSE: LR23) ("Numinus" or the "Company") a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based... Keep Reading...

Latest Press Releases

Related News